Bevacizumab plus chemotherapy versus combination chemotherapy only in metastatic, recurrent, and persistent cervical cancer

被引：0
|
作者：
Choi, H. [1 ]
Kim, B. G. [2 ]
Lee, Y. Y. [3 ]
机构：
[1] Chung Ang Univ, Seoul, South Korea
[2] Sungkyunkwan Univ, Sch Med, Seoul, South Korea
[3] Samsung Med Ctr, Seoul, South Korea
来源：
GYNECOLOGIC ONCOLOGY | 2019年 / 154卷
关键词：
D O I：
10.1016/j.ygyno.2019.04.642
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2537
引用
收藏
页码：275 / 275
页数：1
相关论文
共 50 条
  • [31] Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis
    Shui, Lin
    Wu, Yu-Shen
    Lin, Huapeng
    Shui, Pixian
    Sun, Qin
    Chen, Xiaopin
    [J]. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2018, 48 (05) : 1870 - 1881
  • [32] BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN METASTATIC COLORECTAL CANCER - THE MCGILL EXPERIENCE
    Wasserman, D. W.
    Bouganim, N.
    Batist, G.
    Ferrario, C.
    Kavan, P.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 217 - 217
  • [33] Camrelizumab plus famitinib versus camrelizumab alone and investigator's choice of chemotherapy in women with recurrent or metastatic cervical cancer
    Wu, X.
    Xia, L.
    Zhang, K.
    Tang, Y.
    Zhang, G. N.
    Wang, D.
    Lou, H.
    Liu, N.
    Zhang, H.
    Chen, H.
    Wang, K.
    Wei, S.
    Wang, L.
    Gao, K.
    Li, G.
    Zhang, H.
    Hu, Y.
    Zhou, X.
    Wang, Y.
    Wang, Q.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1284 - S1285
  • [34] Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy
    Hong, Yong Sang
    Lee, Jeeyun
    Kim, Kyu-pyo
    Lee, Jae-Lyun
    Park, Young Suk
    Park, Joon Oh
    Park, Se Hoon
    Kim, Sun Young
    Baek, Ji Yeon
    Kim, Jee Hyun
    Lee, Keun-Wook
    Kim, Tae-You
    Kim, Tae Won
    [J]. INVESTIGATIONAL NEW DRUGS, 2013, 31 (01) : 183 - 191
  • [35] Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy
    Yong Sang Hong
    Jeeyun Lee
    Kyu-pyo Kim
    Jae-Lyun Lee
    Young Suk Park
    Joon Oh Park
    Se Hoon Park
    Sun Young Kim
    Ji Yeon Baek
    Jee Hyun Kim
    Keun-Wook Lee
    Tae-You Kim
    Tae Won Kim
    [J]. Investigational New Drugs, 2013, 31 : 183 - 191
  • [36] Feasibility study on combination chemotherapy using nogitecan hydrochloride (topotecan) and cisplatin for patients with metastatic, persistent, or recurrent uterine cervical cancer
    Shimada, Muneaki
    Sato, Shinya
    Oishi, Tetsuro
    Itamochi, Hiroaki
    Kigawa, Junzo
    Takeshima, Nobuhiro
    Aoki, Daisuke
    Aoki, Yoichi
    Nambu, Yoshihiro
    Ochiai, Kazunori
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2016, 21 (05) : 969 - 974
  • [37] Feasibility study on combination chemotherapy using nogitecan hydrochloride (topotecan) and cisplatin for patients with metastatic, persistent, or recurrent uterine cervical cancer
    Muneaki Shimada
    Shinya Sato
    Tetsuro Oishi
    Hiroaki Itamochi
    Junzo Kigawa
    Nobuhiro Takeshima
    Daisuke Aoki
    Yoichi Aoki
    Yoshihiro Nambu
    Kazunori Ochiai
    [J]. International Journal of Clinical Oncology, 2016, 21 : 969 - 974
  • [38] Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer
    Ilhan, Yusuf
    Tatli, Ali Murat
    Teker, Fatih
    Onder, Arif Hakan
    Kose, Fatih
    Geredeli, Caglayan
    Karaagac, Mustafa
    Kaplan, Muhammet Ali
    Inanc, Mevlude
    Aydin, Sabin Goktas
    Kargi, Aysegul
    Arak, Haci
    Ozturk, Banu
    Besen, Ali Ayberk
    Selvi, Oguzhan
    Korkmaz, Mustafa
    Oruc, Zeynep
    Bozkurt, Oktay
    Bilici, Ahmet
    Bayram, Selami
    Dae, Shute Ailia
    Ozdogan, Mustafa
    Coskun, Hasan Senol
    Goksu, Sema Sezgin
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 (04) : 502 - 507
  • [39] Outcomes of third line chemotherapy for recurrent and persistent cervical cancer
    Manders, D. B.
    Purinton, S. C.
    Lea, J. S.
    Miller, D. S.
    Kehoe, S. M.
    Richardson, D. L.
    [J]. GYNECOLOGIC ONCOLOGY, 2011, 123 (02) : 442 - 443
  • [40] Intraperitoneal chemotherapy without bevacizumab versus intravenous chemotherapy plus bevacizumab as frontline therapy in advanced ovarian cancer
    Ting, Wan Hua Stella
    Wang, Hsiao-Feng
    Chen, Hui-Hua
    Sun, Hsu-Dong
    Wei, Ming-Chow
    Hsiao, Sheng-Mou
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A205 - A206
12345